| Role of chemotherapy in epithelial ovarian cancer. | |
| | |
MedLine Citation:
|
PMID: 21654613 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Despite the fact the standard-of-care primary chemotherapy strategy in epithelial ovarian cancer has undergone very limited changes over the past decade there have been important advances in treatment outcomes resulting from data generated in evidence-based trials that has modified the paradigm for second-line disease management. Recently reported data suggest novel classes of agents, including anti-angiogenic drugs and PARP inhibitors may add to the established utility of standard cytotoxic chemotherapy. |
| | |
Authors:
|
M Markman |
Related Documents
:
|
21801563 - Are the serious problems in cancer survival partly rooted in gatekeeper principles? an ... 21642683 - Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. 9797693 - Is steroid receptor profile in contralateral breast cancer a marker of independence of ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Minerva ginecologica Volume: 63 ISSN: 0026-4784 ISO Abbreviation: Minerva Ginecol Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-06-09 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0400731 Medline TA: Minerva Ginecol Country: Italy |
Other Details:
|
Languages: eng Pagination: 287-97 Citation Subset: IM |
Affiliation:
|
Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, PA, USA - maurie.markman@ctca-hope.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Selective estrogen receptor modulators: the future in menopausal treatment.
Next Document: Pharmacological profile of estrogens in oral contraception.